Join Dr. Mark Kirchhof Oct 18, 8pm ET for virtual review of “Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches” (Blauvelt et al, Br J Dermatol, Jun 2018).

Please join Dr. Mark Kirchhof for WEBINAR 4 of 2018 to be held Thursday, October 18 at 8pm EST, focused on the recent article in the British Journal of Dermatology by Blauvelt et al:

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

NOTE: If you would like a full-text copy of the article above, please contact paul.abbass@legitimed.com

For webinar access details, see calendar invitation.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com

Join Dr. Gordon Searles Sep 20, 8pm ET for virtual review of “Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies” (Numan et al, Adv Ther, Sep 2018).

Please join Dr. Gordon Searles for WEBINAR 3 of 2018 to be held Thursday, September 20 at 8pm EST, focused on the recent article in Advances in Therapy by Numan et al:

Link to full text article: Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

For webinar access details, see calendar invitation.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com